datamatters24/research-document-archive huggingface dataset:
I 
109TH CONGRESS 
1ST SESSION H. R. 1887 
To suspend temporarily the duty on Spiroxamine. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Spiroxamine. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SPIROXAMINE. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.81 
8-(1,1-dimethylethyl)-N- 
ethyl-N-propyl-1,4- 
diozaspiro[4,5]decane-2- 
methanamine (CAS No. 
118134–30–8) (provided for 
in subheading 2932.99.90) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2142 
To suspend temporarily the duty on 1,6-Hexanediamine, N,N’- bis(2,2,6,6- 
tetramethyl-4- piperidinyl)-, polymer with 2,4,6-trichloro-1,3,5-triazine, 
reaction products with N-butyl- 1-butanamine and N-butyl- 2,2,6,6- 
tetramethyl-4- piperidinamine. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BERRY introduced the following bill; which was referred to the Committee 
on Ways and Means 
A BILL 
To suspend temporarily the duty on 1,6-Hexanediamine, 
N,N’- bis(2,2,6,6-tetramethyl-4- piperidinyl)-, polymer 
with 2,4,6-trichloro-1,3,5-triazine, reaction products with 
N-butyl- 1-butanamine and N-butyl- 2,2,6,6-tetramethyl- 
4- piperidinamine. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 
1. 
1,6-HEXANEDIAMINE, 
N,N′- 
BIS(2,2,6,6- 
TETRAMETHYL-4- PIPERIDINYL)-, POLYMER 
WITH 2,4,6-TRICHLORO-1,3,5-TRIAZINE, REAC-
TION 
PRODUCTS 
WITH 
N-BUTYL- 
1- 
BUTANAMINE 
AND 
N-BUTYL- 
2,2,6,6- 
TETRAMETHYL-4- PIPERIDINAMINE. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.54 
1,6-Hexanediamine, N,N′- 
bis(2,2,6,6-tetramethyl-4- 
piperidinyl)-, polymer with 
2,4,6-trichloro-1,3,5-triazine, 
reaction products with N- 
butyl- 1-butanamine and N- 
butyl- 2,2,6,6-tetramethyl-4- 
piperidinamine (CAS No. 
192268–64–7) (provided for 
in subheading 3911.90.90) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
103 
SEC. 119. COVERAGE FOR INDIVIDUALS PARTICIPATING IN 
APPROVED CLINICAL TRIALS. 
(a) COVERAGE.— 
(1) IN GENERAL.—If a group health plan, or 
health insurance issuer that is providing health in-
surance coverage, provides coverage to a qualified in-
dividual (as defined in subsection (b)), the plan or 
issuer— 
(A) may not deny the individual participa-
tion in the clinical trial referred to in subsection 
(b)(2); 
(B) subject to subsection (c), may not deny 
(or limit or impose additional conditions on) the 
coverage of routine patient costs for items and 
services furnished in connection with participa-
tion in the trial; and 
(C) may not discriminate against the indi-
vidual on the basis of the enrollee’s participa-
tion in such trial. 
(2) EXCLUSION OF CERTAIN COSTS.—For pur-
poses of paragraph (1)(B), routine patient costs do 
not include the cost of the tests or measurements 
conducted primarily for the purpose of the clinical 
trial involved. 
(3) USE OF IN-NETWORK PROVIDERS.—If one 
or more participating providers is participating in a
104 
clinical trial, nothing in paragraph (1) shall be con-
strued as preventing a plan or issuer from requiring 
that a qualified individual participate in the trial 
through such a participating provider if the provider 
will accept the individual as a participant in the 
trial. 
(b) QUALIFIED INDIVIDUAL DEFINED.—For pur-
poses of subsection (a), the term ‘‘qualified individual’’ 
means an individual who is a participant or beneficiary 
in a group health plan, or who is an enrollee under health 
insurance coverage, and who meets the following condi-
tions: 
(1) (A) The individual has a life-threatening or 
serious illness for which no standard treatment is ef-
fective. 
(B) The individual is eligible to participate in 
an approved clinical trial according to the trial pro-
tocol with respect to treatment of such illness. 
(C) The individual’s participation in the trial 
offers meaningful potential for significant clinical 
benefit for the individual. 
(2) Either— 
(A) the referring physician is a partici-
pating health care professional and has con-
cluded that the individual’s participation in
I 
109TH CONGRESS 
1ST SESSION H. R. 1888 
To suspend temporarily the duty on Spiromesifen. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Spiromesifen. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SPIROMESIFEN. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.82 
2-oxo-3-(2,4,6- 
trimethylphenyl)–1- 
oxaspiro[4.4]non-3-en-4-yl 
3,3-dimethylbutanoate (CAS 
No. 283594–90–1) (provided 
for in subheading 
2932.29.10) .........................
Free 
No change 
No change 
On or before 
12/31/2008 
’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2143
To suspend temporarily the duty on Anthra[2,1,9-mna]naphth[2,3-h]acridine-
5,10,15(16H)-trione,3-[(9,10-dihydro-9,10-dioxo-1-anthracenyl)amino]-. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005
Mr. BERRY introduced the following bill; which was referred to the Committee 
on Ways and Means 
A BILL 
To 
suspend 
temporarily 
the 
duty 
on 
Anthra[2,1,9-
mna]naphth[2,3-h]acridine-5,10,15(16H)-trione,3-[(9,10-
dihydro-9,10-dioxo-1-anthracenyl)amino]-.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 
1. 
ANTHRA[2,1,9-MNA]NAPHTH[2,3-H]ACRIDINE-
5,10,15(16H)-TRIONE,3-[(9,10-DIHYDRO-9,10-
DIOXO-1-ANTHRACENYL)AMINO]-. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading:
‘‘
9902.06.71
Anthra[2,1,9-
mna]naphth[2,3-h]acridine-
5,10,15(16H)-trione,3-
[(9,10-dihydro-9,10-dioxo-1-
anthracenyl)amino]- (CAS 
No. 4395–53–3) (provided 
for in subheading 
3204.15.80) .........................
Free 
No change 
No change 
On or before 
12/31/2008
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act.
Æ
105 
such trial would be appropriate based upon the 
individual meeting the conditions described in 
paragraph (1); or 
(B) the participant, beneficiary, or enrollee 
provides medical and scientific information es-
tablishing that the individual’s participation in 
such trial would be appropriate based upon the 
individual meeting the conditions described in 
paragraph (1). 
(c) PAYMENT.— 
(1) IN GENERAL.—Under this section a group 
health plan and a health insurance issuer shall pro-
vide for payment for routine patient costs described 
in subsection (a)(2) but is not required to pay for 
costs of items and services that are reasonably ex-
pected (as determined by the appropriate Secretary) 
to be paid for by the sponsors of an approved clin-
ical trial. 
(2) PAYMENT RATE.—In the case of covered 
items and services provided by— 
(A) a participating provider, the payment 
rate shall be at the agreed upon rate; or 
(B) a nonparticipating provider, the pay-
ment rate shall be at the rate the plan or issuer
106 
would normally pay for comparable services 
under subparagraph (A). 
(d) APPROVED CLINICAL TRIAL DEFINED.— 
(1) IN
GENERAL.—In this section, the term 
‘‘approved clinical trial’’ means a clinical research 
study or clinical investigation— 
(A) approved and funded (which may in-
clude funding through in-kind contributions) by 
one or more of the following: 
(i) the National Institutes of Health; 
(ii) a cooperative group or center of 
the National Institutes of Health, includ-
ing a qualified nongovernmental research 
entity to which the National Cancer Insti-
tute has awarded a center support grant; 
(iii) either of the following if the con-
ditions described in paragraph (2) are 
met— 
(I) the Department of Veterans 
Affairs; 
(II) the Department of Defense; 
or 
(B) approved by the Food and Drug Ad-
ministration.
gressional Budget Act of 1974 (as amended by section 
116) is further amended by adding after section 316 the 
following new section: 
‘‘EXPEDITED PROCEDURES UPON VETO OF JOINT 
RESOLUTION ON THE BUDGET 
‘‘SEC. 317. (a) SPECIAL RULE.—If the President ve-
toes a joint resolution on the budget for a fiscal year, the 
majority leader of the House of Representatives or Senate 
(or his designee) may introduce a concurrent resolution 
on the budget or joint resolution on the budget for such 
fiscal year. If the Committee on the Budget of either 
House fails to report such concurrent or joint resolution 
referred to it within five calendar days (excluding Satur-
days, Sundays, or legal holidays except when that House 
of Congress is in session) after the date of such referral, 
the committee shall be automatically discharged from fur-
ther consideration of such resolution and such resolution 
shall be placed on the appropriate calendar. 
‘‘(b) PROCEDURE IN THE HOUSE OF REPRESENTA-
TIVES AND THE SENATE.— 
‘‘(1) Except as provided in paragraph (2), the 
provisions of section 305 for the consideration in the 
House of Representatives and in the Senate of joint 
resolutions on the budget and conference reports 
thereon shall also apply to the consideration of con-
106TH CONGRESS
2D SESSION
H. CON. RES. 232
CONCURRENT RESOLUTION
Expressing the sense of the Congress concerning
the safety and well-being of United States citi-
zens injured while traveling in Mexico.
I 
109TH CONGRESS 
1ST SESSION H. R. 2144 
To suspend temporarily the duty on Cobaltate(1-), bis[3-[[1-(3- chlorophenyl)– 
4,5-dihydro-3- methyl-5-(oxo-.kappa.O)–1H- pyrazol-4-yl]azo-.kappa.N1]- 
4-. (hydroxy-.kappa.O)- benzenesulfonamid- ato(2-)]-, sodium. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BERRY introduced the following bill; which was referred to the Committee 
on Ways and Means 
A BILL 
To suspend temporarily the duty on Cobaltate(1-), bis[3- 
[[1-(3- 
chlorophenyl)–4,5-dihydro-3- 
methyl-5-(oxo- 
.kappa.O)–1H- pyrazol-4-yl]azo-.kappa.N1]-4-. (hydroxy- 
.kappa.O)- benzenesulfonamid- ato(2-)]-, sodium. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. COBALTATE(1-), BIS[3-[[1-(3- CHLOROPHENYL)– 
4,5-DIHYDRO-3- METHYL-5-(OXO-.KAPPA.O)–1H- 
PYRAZOL-4-YL]AZO-.KAPPA.N1]-4- 
(HYDROXY- 
.KAPPA.O)- BENZENESULFONAMID- ATO(2-)]-, 
SODIUM. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.55 
Cobaltate(1-), bis[3-[[1-(3- 
chlorophenyl)–4,5-dihydro-3- 
methyl-5-(oxo-.kappa.O)– 
1H- pyrazol-4-yl]azo- 
.kappa.N1]-4- (hydroxy- 
.kappa.O)- 
benzenesulfonamid- ato(2-)]- 
, sodium (CAS No. 73612– 
40–5) (provided for in sub-
heading 3204.12.45) ............
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 1889 
To extend the temporary suspension of duty on Ethoprop. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To extend the temporary suspension of duty on Ethoprop. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. ETHOPROP. 
(a) IN GENERAL.—Heading 9902.01.83 of the Har-
monized Tariff Schedule of the United States is amended 
by striking ‘‘12/31/2006’’ and inserting ‘‘12/31/2008’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2145 
To suspend temporarily the duty on TMQ. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BROWN of South Carolina introduced the following bill; which was 
referred to the Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on TMQ. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. TMQ. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.06.09 
2,2,4-Trimethyl-1,2- 
dihydroquinoline polymer 
(CAS No. 26780–96–1) 
(provided for in subheading 
3812.30.60) .........................
Free 
No change 
No change 
On or before 
12/31/2009 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
107 
(2) CONDITIONS
FOR
DEPARTMENTS.—The 
conditions described in this paragraph, for a study 
or investigation conducted by a Department, are 
that the study or investigation has been reviewed 
and approved through a system of peer review that 
the appropriate Secretary determines— 
(A) to be comparable to the system of peer 
review of studies and investigations used by the 
National Institutes of Health; and 
(B) assures unbiased review of the highest 
ethical standards by qualified individuals who 
have no interest in the outcome of the review. 
(e) CONSTRUCTION.—Nothing in this section shall be 
construed to limit a plan’s or issuer’s coverage with re-
spect to clinical trials. 
SEC. 120. REQUIRED COVERAGE FOR MINIMUM HOSPITAL 
STAY FOR MASTECTOMIES AND LYMPH NODE 
DISSECTIONS 
FOR 
THE 
TREATMENT 
OF 
BREAST CANCER AND COVERAGE FOR SEC-
ONDARY CONSULTATIONS. 
(a) INPATIENT CARE.— 
(1) IN GENERAL.—A group health plan, and a 
health insurance issuer providing health insurance 
coverage, that provides medical and surgical benefits 
shall ensure that inpatient coverage with respect to
108 
the treatment of breast cancer is provided for a pe-
riod of time as is determined by the attending physi-
cian, in consultation with the patient, to be medi-
cally necessary and appropriate following— 
(A) a mastectomy; 
(B) a lumpectomy; or 
(C) a lymph node dissection for the treat-
ment of breast cancer. 
(2) EXCEPTION.—Nothing in this section shall 
be construed as requiring the provision of inpatient 
coverage if the attending physician and patient de-
termine that a shorter period of hospital stay is 
medically appropriate. 
(b) PROHIBITION ON CERTAIN MODIFICATIONS.—In 
implementing the requirements of this section, a group 
health plan, and a health insurance issuer providing health 
insurance coverage, may not modify the terms and condi-
tions of coverage based on the determination by a partici-
pant, beneficiary, or enrollee to request less than the min-
imum coverage required under subsection (a). 
(c) SECONDARY CONSULTATIONS.— 
(1) IN GENERAL.—A group health plan, and a 
health insurance issuer providing health insurance 
coverage, that provides coverage with respect to 
medical and surgical services provided in relation to
current resolutions on the budget introduced under 
subsection (a) and conference reports thereon. 
‘‘(2) Debate in the Senate on any concurrent 
resolution on the budget or joint resolution on the 
budget introduced under subsection (a), and all 
amendments thereto and debatable motions and ap-
peals in connection therewith, shall be limited to not 
more than 10 hours and in the House such debate 
shall be limited to not more than 3 hours. 
‘‘(c) CONTENTS OF CONCURRENT RESOLUTIONS.— 
Any concurrent resolution on the budget introduced under 
subsection (a) shall be in compliance with section 301. 
‘‘(d) EFFECT OF CONCURRENT RESOLUTION ON THE 
BUDGET.—Notwithstanding any other provision of this 
title, whenever a concurrent resolution on the budget de-
scribed in subsection (a) is agreed to, then the aggregates, 
allocations, and reconciliation directives (if any) contained 
in the report accompanying such concurrent resolution or 
in such concurrent resolution shall be considered to be the 
aggregates, allocations, and reconciliation directives for all 
purposes of sections 302, 303, and 311 for the applicable 
fiscal years and such concurrent resolution shall be 
deemed to be a joint resolution for all purposes of this 
title and the Rules of the House of Representatives and 
any reference to the date of enactment of a joint resolution
I 
109TH CONGRESS 
1ST SESSION H. R. 2146 
To suspend temporarily the duty on 4-ADPA. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BROWN of South Carolina introduced the following bill; which was 
referred to the Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on 4-ADPA. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. 4-ADPA. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.06.07 
4-Aminodiphenylamine (CAS 
No. 101–54–2) (provided for 
in subheading 2921.51.50) ..
Free 
No change 
No change 
On or before 
12/31/2009 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
I 
109TH CONGRESS 
1ST SESSION H. R. 1890 
To suspend temporarily the duty on Propiconazole. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Propiconazole. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. PROPICONAZOLE. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.84 
(RS)–1-[2-(2,4- 
dichlorophenyl)–4-n-propyl- 
1,3-dioxolan-2-ylmethyl]-1H- 
1,2,4-triazole (CAS No. 
60207–90–1) (provided for 
in subheading 2934.99.12) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
106TH CONGRESS
1ST SESSION
H. CON. RES. 235
CONCURRENT RESOLUTION
Providing for an conditional sine die adjournment
of the first session of the One Hundred Sixth
Congress.
I 
109TH CONGRESS 
1ST SESSION H. R. 1891 
To suspend temporarily the duty on 4-Chlorobenzaldehyde. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on 4-Chlorobenzaldehyde. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. 4-CHLOROBENZALDEHYDE. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.85 
4-Chlorobenzaldehyde (CAS 
No. 104–88–1) (provided for 
in subheading 2913.00.40) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2147 
To suspend temporarily the duty on Vulkanox MB (MBI). 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BROWN of South Carolina introduced the following bill; which was 
referred to the Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Vulkanox MB (MBI). 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. VULKANOX MB (MBI). 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.06.01 
2-Mercaptobenzimidiazole 
(CAS No. 583–39–1) (pro-
vided for in subheading 
2933.99.82) .........................
Free 
No change 
No change 
On or before 
12/31/2009 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
112 
(B) PARTICIPANTS, BENEFICIARIES, AND 
ENROLLEES.—The disclosure required under 
subparagraph (A) shall be provided— 
(i) jointly to each participant, bene-
ficiary, and enrollee who reside at the same 
address; or 
(ii) in the case of a beneficiary or en-
rollee who does not reside at the same ad-
dress as the participant or another en-
rollee, separately to the participant or 
other enrollees and such beneficiary or en-
rollee. 
(2) PROVISION OF INFORMATION.—Information 
shall be provided to participants, beneficiaries, and 
enrollees under this section at the last known ad-
dress maintained by the plan or issuer with respect 
to such participants, beneficiaries, or enrollees, to 
the extent that such information is provided to par-
ticipants, beneficiaries, or enrollees via the United 
States Postal Service or other private delivery serv-
ice. 
(b) REQUIRED INFORMATION.—The informational 
materials to be distributed under this section shall include 
for each option available under the group health plan or 
health insurance coverage the following:
113 
(1) BENEFITS.—A description of the covered 
benefits, including— 
(A) any in- and out-of-network benefits; 
(B) specific preventive services covered 
under the plan or coverage if such services are 
covered; 
(C) any specific exclusions or express limi-
tations 
of 
benefits 
described 
in 
section 
104(d)(3)(C); 
(D) any other benefit limitations, including 
any annual or lifetime benefit limits and any 
monetary limits or limits on the number of vis-
its, days, or services, and any specific coverage 
exclusions; and 
(E) any definition of medical necessity 
used in making coverage determinations by the 
plan, issuer, or claims administrator. 
(2) COST SHARING.—A description of any cost- 
sharing requirements, including— 
(A) any premiums, deductibles, coinsur-
ance, copayment amounts, and liability for bal-
ance billing, for which the participant, bene-
ficiary, or enrollee will be responsible under 
each option available under the plan;